efgartigimod

Key facts

Mechanism of action

IgG receptor FcRn large subunit p51 antagonist

Primary target: IgG receptor FcRn large subunit p51

Approval history

1. ARGX-113-2308 Phase 3 · Argenx · Acetylcholine Receptor Binding Antibody Seronegative General
2. ARGX-113-2309 Phase 3 · Argenx · Thyroid Eye Disease (TED)
3. ARGX-113-2402 Phase 3 · Argenx · Primary Immune thrombocytopenia (ITP)
4. EFGARTIGIMOD ALFA, JNJ-80202135 Phase 3 · Janssen-Cilag International N.V · generalized myasthenia gravis
5. Efgartigimod PH20 SC Phase 3 · Argenx · Primary Sjogrens Disease
6. Efgartigimod, Placebo for efgartigimod Phase 3 · Argenx · Thyroid Eye Disease (TED)
7. Placebo for efgartigimod, ARGX-113 Phase 3 · Argenx · Chronic Idiopathic thrombocytopenic purpura
8. efgartigimod PH20 SC Phase 3 · Argenx · Bullous Pemphigoid

1. efgartigimod alfa Antineoplastic and immunomodulating agents (L04)
2. rozanolixizumab-noli IgG receptor FcRn large subunit p51 inhibitor
3. nipocalimab Antineoplastic and immunomodulating agents (L04)
4. rozanolixizumab Antineoplastic and immunomodulating agents (L04)

Frequently asked questions